专利号:US-9051302-B2 优先权日:2008-01-15 标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents 发明人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN 权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG 摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.
专利号:WO-9709067-A1 优先权日:1995-09-05 标 题 :Combination of 5-lipoxygenase and leukotriene synthesis inhibitors with glucocorticosteroids 发明人:BURCHARDT ELMAR-REINHOLD; MUELLER-PEDDINGHAUS REINER 权利人:BAYER AG; BURCHARDT ELMAR REINHOLD; MUELLER PEDDINGHAUS REINER 摘要:The combination is disclosed of 5-lipoxygenase inhibitors as direct action lipoxygenase inhibitors (LOI) or of leukotriene synthesis inhibitors (LSI) with glucocorticosteroids (GCS). This combination is suitable for treating and preventing various acute and chronic inflammatory processes, in particular of the respiratory tract, and may therefore be used as a medicament, in particular for treating asthma.
专利号:US-2021244638-A1 优先权日:2018-06-05 标 题:Inhibitors of glycosphingolipid synthesis and methods of use 发明人:CHATTERJEE SUBROTO B 权利人:SUBROTO B CHATTERJEE 摘要:Compositions in the prevention and treatment of skin diseases or associated disorders, inflammation or inflammatory diseases or disorders, include at least one inhibitor of glycosphingolipid synthesis.
专利号:WO-2024233563-A1 优先权日:2023-05-09 标 题:6,6-fused bicyclic amides and compositions for use as 15-prostaglandin dehydrogenase modulators 发明人:GREENMAN KEVIN LLOYD; WANG HUI-LING; WEIRES NICHOLAS ANTHONY; ALLEN JOHN G; AMEGADZIE ALBERT K; BOURBEAU MATTHEW P; LI KEXUE 权利人:AMGEN INC 摘要:The present disclosure provides novel 15-hydroxy-prostaglandin dehydrogenase inhibitors, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions in treating 15-hydroxy-prostaglandin dehydrogenase-mediated disease. Also provided are methods of making such compounds and intermediates thereof. The compounds have a structure of Formula (I): or a pharmaceutically acceptable salt thereof; wherein is Formula (i) or Formula (ii) Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
专利号:US-2024409557-A1 优先权日:2023-05-09 标 题 :5,6-fused and 6,6-fused bicyclic alcohols and ethers and compositions for use as 15-prostaglandin dehydrogenase modulators 发明人:GREENMAN KEVIN LLOYD; PICKRELL ALEXANDER J; LI KEXUE; AMEGADZIE ALBERT K; WANG HUI-LING; WEIRES NICHOLAS ANTHONY; ALLEN JOHN G; BOURBEAU MATTHEW P 权利人:AMGEN INC 摘要:The present disclosure provides novel 15-hydroxy-prostaglandin dehydrogenase inhibitors, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions in treating 15-hydroxy-prostaglandin dehydrogenase-mediated disease. Also provided are methods of making such compounds and intermediates thereof. The compounds have a general Formula (A).Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (A).
专利号:US-10239856-B2 优先权日:2008-01-15 标题:Synthesis of resorcylic acid lactones useful as therapeutic agents
1: Hayashi S, Akao N, Okamoto K. Meningeal plasma cell granuloma in the early stage of relapsing polychondritis. Rinsho Shinkeigaku. 2017 May 26. doi: 10.5692/clinicalneurol.cn-000975. [Epub ahead of print] doi: 10.20344/amp.7297. Epub 2017 Mar 31. Portuguese. . Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017 May 25. pii: annrheumdis-2017-211123. doi: 10.1136/annrheumdis-2017-211123. [Epub ahead of print] doi: 10.3315/jdcr.2017.1243. eCollection 2017 Mar 31. 13: Saito A, Takeuchi Y, Kagaya S, Ojima Y, Fukami H, Sato H, Matsuda K, Nagasawa T. Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study. Tohoku J Exp Med. 2017;242(1):53-62. doi: 10.1620/tjem.242.53. doi: 10.1097/MD.0000000000006968. doi: 10.1097/MD.0000000000006965. pii: E17. doi: 10.3390/pharmaceutics9020017. Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. Lupus. 2017 Jan 1:961203317711009. doi: 10.1177/0961203317711009. [Epub ahead of print]